News

Here's some of what is coming soon to NeurologyLive® this week.

For the majority of patients who were either aquaporin-4-antibody seropositive or seronegative, rituximab was the first disease-modifying therapy administered for neuromyelitis optica spectrum disorder.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on chronic migraine.

Mirdametinib, a treatment in development for adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas, was granted a PDUFA target action date of February 28, 2025.

Neurology News Network. for the week ending August 31, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 30, 2024.

The FDA has granted fast track designation to [18F]PI-2620 for 3 neurodegenerative conditions, highlighting its potential to improve early diagnosis and treatment.

The study highlighted semaglutide's lower risk of adverse neurological outcomes, making it a promising candidate for future neuroprotective therapies, including ongoing trials for Alzheimer disease.

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed the parameters of an upcoming educational event that highlights the current and future role of sEEG in epilepsy surgery. [WATCH TIME: 5 minutes]

The analysis revealed a significant link between the proportion of AQP4 antibody-positive cases and a higher female-to-male sex ratio in NMOSD.

The submission was based on results from the phase 3 Vivacity-MG3 study, which demonstrated nipocalimab’s superiority over placebo when added to standard of care in patients with generalized myasthenia gravis.

ABA-101 has shown promising safety and anti-inflammatory effects in animal models, and Abata Therapeutics plans to initiate a Phase 1 study in 2024 to evaluate its potential for treating progressive multiple sclerosis.

Phase 1b trials involving patients with Parkinson are planned for late 2024, with data expected by mid-2025.

Study authors concluded that enhanced pre-pregnancy counseling and specialized perinatal care are crucial for safer outcomes in pregnant women with epilepsy.

The chairman and chief executive officer at Biomed discussed the additive benefits of combination therapy for Alzheimer disease, providing context on the strengths of different drugs and how it might lead to a more precision medicine approach. [WATCH TIME: 6 minutes]

The published data provided preliminary evidence that AMX0035 engages Alzheimer disease pathology and pathways of neurodegeneration, synaptic function, gliosis, and oxidative stress.

Findings from a recent study analyzing 3 cohorts suggested that certain proteins in the cerebrospinal fluid may have potential as biomarkers or therapeutic targets in progressive supranuclear palsy.

Investigational drug CT1812 showed potential to improve neurophysiological markers in mild-to-moderate Alzheimer's disease, with notable EEG changes observed in a recent phase 2 study.

The chief executive officer and chief medical officer at Quince Therapeutics talked about recent findings from the phase 3 ATTeST study assessing EryDex in pediatric patients with ataxia telangiectasia.

The director of neurology and neuromuscular medicine at the Children’s Hospital of the King’s Daughters in Norfolk, Virginia, discussed SMA Awareness Month and the enhancements to newborn screening for the disease. [WATCH TIME: 4 minutes]

Steve Herne, chief commercial officer at Unlearn, provided context on a recently conducted study assessing the company’s digital twin methodology AI tool to enhance the statistical certainty of Alzheimer trials.

A recent cohort study reported that use of enzyme-inducing antiseizure medications alongside direct-acting oral anticoagulants was not associated with a difference in risk of thromboembolic events.

Vibrance-2 is a double-blind, placebo-controlled trial with 80 participants, assessing three doses of ALKS 2680 over eight weeks

A recent prospective study reveals significant alterations in heavy metal and trace element levels among patients with migraine, suggesting these imbalances may play a role in the pathogenesis and progression of the condition.

IMU-838 daily doses of 30-mg and 45-mg suppressed the development of gadolinium-enhancing lesions by 78% and 74% compared with the placebo at 24 weeks in relapsing-remitting multiple sclerosis.

William Hu, MD, PhD, FAAN, a neurologist at RWJBarnabas Health’s Robert Wood Johnson University Hospital in New Brunswick, NJ, shared new advances to detect and treat Alzheimer disease.

EryDex did not meet its primary end point possibly because of delays in treatment reducing the number of patients who received the agent, and different treatment effects based on age.

The postdoctoral researcher at Amsterdam University Medical Center introduces the DAAE score, a tool used to predict a patient's risk of transition to secondary progressive multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

DT-216P2 shows promise in treating patients with Friedreich ataxia based on positive phase 1 trial results that indicated a significant increase in frataxin mRNA levels.